News flow has been a mixed bag in the last 2 3 weeks.
While deleveraging and pre paying debt, renewed focus on Radiopharmaceuticals, Roorkee Generics UDFDA clearance and New Management are good ones.
USFDA adverse observations at Both Canada and USA plants don’t augur well. These plants are into CDMO sterile (most tricky from compliance POV), Allergy and Radiopharmaceuticals.
The stock is also also confused and hovering around 700 plus minus.
Not sure on the scope of revenue affected by adverse USFDA observations(Communication says Contract Manufacturing affected) . Spokane is already undergoing expansion with capacities expected to go live in FY26 and FY28.
| Subscribe To Our Free Newsletter |
